PD-L1 Protein (AA 19-238)

Catalog No. ABIN7597400

This Recombinant PD-L1 protein is expressed in HEK-293 Cells.

Quick Overview for PD-L1 Protein (AA 19-238) (ABIN7597400)

Target: PD-L1 (CD274 (PD-L1))

Protein Type: Recombinant

Origin: Human

Source: HEK-293 Cells

Purity: The purity of the protein is greater than 95 % as determined by SDS-PAGE and Coomassie blue staining.

Product Details

Protein Characteristics: AA 19-238

Purpose: Recombinant human PD-L1 Protein

Sequence: PD-L1(Phe19-Arg238)

Application Details

Application Notes: Extracellular Domain Proteins (ECD) can be used as:

• Immunogens for antibody drug development
• Reagents used for CAR-T positive cell monitoring
• Reagents for antibody screening and functional testing
• Reagents for antibody affinity measurement

Comment:

The protein was made using HEK293 mammalian cell secretion expression system to ensure the close-to-native structures and post-translational modifications of the target protein.

Restrictions: For Research Use only

Handling

Format: Lyophilized

Buffer: Lyophilized from sterile PBS, pH 7.4. Normally 5 % – 8% trehalose is added as protectants before lyophilization.

Storage: -20 °C,-80 °C

Storage Comment: Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.

Expiry Date: 12 months

Target Details

Target: PD-L1 (CD274 (PD-L1))

Alternative Name: PD-L1

Background: B7-H, B7H1, PDL1, CD274, hPD-L1, PDCD1L1, PDCD1LG1
This gene encodes an immune inhibitory receptor ligand that is expressed by hematopoietic and non-hematopoietic cells, such as T cells and B cells and various types of tumor cells. The encoded protein is a type I transmembrane protein that has immunoglobulin V-like and C-like domains. Interaction of this ligand with its receptor inhibits T-cell activation and cytokine production. During infection or inflammation of normal tissue, this interaction is important for preventing autoimmunity by maintaining homeostasis of the immune response. In tumor microenvironments, this interaction provides an immune escape for tumor cells through cytotoxic T-cell inactivation. Expression of this gene in tumor cells is considered to be prognostic in many types of human malignancies, including colon cancer and renal cell carcinoma. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Sep 2015]

Molecular Weight: predicted molecular mass of 25.9 kDa after removal of the signal peptide.

UniProt: Q9NZQ7

Pathways: Cancer Immune Checkpoints